Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

PHASE3CompletedINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

December 24, 2021

Primary Completion Date

February 18, 2023

Study Completion Date

February 18, 2023

Conditions

Submental Fat

Interventions

DRUG

MT921

Active ingredient

DRUG

Placebo

Normal Saline

Trial Locations (1)

Inha University Hospital, Incheon

All Listed Sponsors

lead

Medy-Tox

INDUSTRY

NCT05195112 - Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat | Biotech Hunter | Biotech Hunter